| Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis (NCT07441408) | Bristol-Myers Squibb | 2026-12-16 |
| A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis (NCT07412704) | Bristol-Myers Squibb | 2026-09-15 |
| A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism (NCT07284745) | Bristol-Myers Squibb | 2026-09-11 |
| A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function (NCT07763418) | Bristol-Myers Squibb | 2026-08-24 |
| First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms (NCT07752121) | Bristol-Myers Squibb | 2026-08-24 |
| A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT07680764) | Bristol-Myers Squibb | 2026-08-15 |
| Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis (NCT07722507) | Bristol-Myers Squibb | 2026-08-01 |
| A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (NCT07492680) | Bristol-Myers Squibb | 2026-07-27 |
| Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants (NCT07629999) | Bristol-Myers Squibb | 2026-07-13 |
| A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants (NCT07655518) | Bristol-Myers Squibb | 2026-06-25 |
| A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (NCT07215975) | Bristol-Myers Squibb | 2026-06-25 |
| Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia (NCT07732907) | Bristol-Myers Squibb | 2026-06-04 |
| Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion (NCT07599007) | Bristol-Myers Squibb | 2026-05-24 |
| A Phase 1 Study of Navlimetostat Tablet Formulations (NCT07544628) | Bristol-Myers Squibb | 2026-04-27 |
| A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring (NCT05953402) | Bristol-Myers Squibb | 2026-04-21 |
| Asia Myelodysplastic Syndrome (MDS) Registry (NCT07355478) | Bristol-Myers Squibb | 2026-03-26 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) (NCT07293351) | Bristol-Myers Squibb | 2026-03-26 |
| A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) (NCT06947941) | Bristol-Myers Squibb | 2026-03-25 |
| A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (NCT07291076) | Bristol-Myers Squibb | 2026-03-16 |
| A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) (NCT07361497) | Bristol-Myers Squibb | 2026-03-16 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (NCT07221149) | Bristol-Myers Squibb | 2026-03-13 |
| A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) (NCT07361510) | Bristol-Myers Squibb | 2026-03-12 |
| First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE) (NCT07679061) | Bristol-Myers Squibb | 2026-03-05 |
| Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada (NCT07718139) | Bristol-Myers Squibb | 2026-02-28 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis (NCT07171983) | Bristol-Myers Squibb | 2026-02-27 |
| Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) (NCT07379827) | Bristol-Myers Squibb | 2026-02-26 |
| A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 (NCT06875960) | Bristol-Myers Squibb | 2026-02-24 |
| A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants (NCT07422298) | Bristol-Myers Squibb | 2026-02-19 |
| Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) (NCT07541833) | Bristol-Myers Squibb | 2026-02-05 |
| A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer (NCT07325136) | Bristol-Myers Squibb | 2026-02-03 |
| A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain (NCT07465029) | Bristol-Myers Squibb | 2026-02-02 |
| Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis (NCT07271069) | Bristol-Myers Squibb | 2026-01-29 |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) (NCT07288567) | Bristol-Myers Squibb | 2026-01-29 |
| A Study to Evaluate the Effect of KarXT on Urological Safety (NCT07221877) | Bristol-Myers Squibb | 2026-01-20 |
| Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users (NCT07571148) | Bristol-Myers Squibb | 2026-01-16 |
| Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US (NCT07557498) | Bristol-Myers Squibb | 2026-01-15 |
| A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (NCT07195682) | Bristol-Myers Squibb | 2026-01-15 |
| A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China (NCT07361289) | Bristol-Myers Squibb | 2026-01-15 |
| A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (NCT07063745) | Bristol-Myers Squibb | 2026-01-02 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (NCT07221357) | Bristol-Myers Squibb | 2025-12-31 |
| Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (NCT07223671) | Bristol-Myers Squibb | 2025-12-31 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants. (NCT07283263) | Bristol-Myers Squibb | 2025-12-23 |
| A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment (NCT07248839) | Bristol-Myers Squibb | 2025-12-15 |
| Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia (NCT07458542) | Bristol-Myers Squibb | 2025-12-09 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis (NCT06979453) | Bristol-Myers Squibb | 2025-12-03 |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) (NCT06937229) | Bristol-Myers Squibb | 2025-12-02 |
| Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland (NCT07526961) | Bristol-Myers Squibb | 2025-12-01 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies (NCT07223047) | Bristol-Myers Squibb | 2025-11-25 |
| Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan (NCT07755826) | Bristol-Myers Squibb | 2025-11-20 |
| A Lactation Study in Women Receiving Treatment With Ozanimod (NCT06181630) | Bristol-Myers Squibb | 2025-11-15 |
| A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants (NCT07226817) | Bristol-Myers Squibb | 2025-11-12 |
| A Study to Assess the Effect of Food on the Drug Levels of Admilparant (NCT07225647) | Bristol-Myers Squibb | 2025-11-07 |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) (NCT07100080) | Bristol-Myers Squibb | 2025-11-05 |
| A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) (NCT07076121) | Bristol-Myers Squibb | 2025-10-23 |
| A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors (NCT07160725) | Bristol-Myers Squibb | 2025-10-15 |
| A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors (NCT07077434) | Bristol-Myers Squibb | 2025-10-15 |
| A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine (NCT07140913) | Bristol-Myers Squibb | 2025-10-08 |
| Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy (NCT07106762) | Bristol-Myers Squibb | 2025-09-30 |
| Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU) (NCT07101094) | Bristol-Myers Squibb | 2025-09-22 |
| A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (NCT06946797) | Bristol-Myers Squibb | 2025-09-19 |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) (NCT06926868) | Bristol-Myers Squibb | 2025-09-11 |
| A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) (NCT06855771) | Bristol-Myers Squibb | 2025-09-09 |
| A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER) (NCT07004972) | Bristol-Myers Squibb | 2025-09-04 |
| A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT (NCT07061288) | Bristol-Myers Squibb | 2025-09-03 |
| Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig (NCT07636863) | Bristol-Myers Squibb | 2025-08-21 |
| Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy (NCT07256015) | Bristol-Myers Squibb | 2025-08-05 |
| A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors (NCT06997029) | Bristol-Myers Squibb | 2025-08-01 |
| A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) (NCT06929273) | Bristol-Myers Squibb | 2025-07-18 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (NCT07011745) | Bristol-Myers Squibb | 2025-07-16 |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (NCT06976216) | Bristol-Myers Squibb | 2025-07-14 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) (NCT07011732) | Bristol-Myers Squibb | 2025-07-10 |
| A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses (NCT07063342) | Bristol-Myers Squibb | 2025-06-27 |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) (NCT06951711) | Bristol-Myers Squibb | 2025-06-13 |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (NCT06951698) | Bristol-Myers Squibb | 2025-06-11 |
| A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia (NCT06882785) | Bristol-Myers Squibb | 2025-06-10 |
| A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC (NCT07141563) | Bristol-Myers Squibb | 2025-05-26 |
| Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (NCT07383025) | Bristol-Myers Squibb | 2025-05-21 |
| Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan (NCT07008820) | Bristol-Myers Squibb | 2025-05-13 |
| Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab (NCT07091695) | Bristol-Myers Squibb | 2025-05-11 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer (NCT06799286) | Bristol-Myers Squibb | 2025-05-07 |
| A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants (NCT06955741) | Bristol-Myers Squibb | 2025-05-05 |
| Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders (NCT06853171) | Bristol-Myers Squibb | 2025-04-29 |
| Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China (NCT07073690) | Bristol-Myers Squibb | 2025-04-18 |
| Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis (NCT06408259) | Bristol-Myers Squibb | 2025-04-08 |
| A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors (NCT06764771) | Bristol-Myers Squibb | 2025-03-25 |
| A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion (NCT06672523) | Bristol-Myers Squibb | 2025-03-24 |
| A Study to Assess Deucravacitinib Safety in Pregnancy (NCT07017699) | Bristol-Myers Squibb | 2025-03-21 |
| A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants (NCT06877702) | Bristol-Myers Squibb | 2025-03-19 |
| A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis (NCT06869551) | Bristol-Myers Squibb | 2025-03-13 |
| A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants (NCT06846866) | Bristol-Myers Squibb | 2025-02-27 |
| A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). (NCT06646276) | Bristol-Myers Squibb | 2025-02-25 |
| A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors (NCT06697197) | Bristol-Myers Squibb | 2025-02-17 |
| A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors (NCT06730750) | Bristol-Myers Squibb | 2025-02-12 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants (NCT06746402) | Bristol-Myers Squibb | 2025-02-10 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors (NCT06618287) | Bristol-Myers Squibb | 2025-02-04 |
| A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults (NCT06851871) | Bristol-Myers Squibb | 2025-01-23 |
| A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China (NCT06512337) | Bristol-Myers Squibb | 2025-01-20 |
| Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens (NCT07689006) | Bristol-Myers Squibb | 2024-12-23 |
| A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants (NCT06715683) | Bristol-Myers Squibb | 2024-12-12 |
| Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France (NCT06504615) | Bristol-Myers Squibb | 2024-12-10 |